The FDA has "repeatedly stated that effectiveness against transmission remains unproven," the trio write, noting that the agency’s website maintains: "the scientific community does not yet know if Comirnaty will reduce such transmission."
Consequently, the Full Committee business meeting, initially scheduled to vote on holding Director Wray in contempt of Congress on Thursday, has been canceled.